옵션 체인은 다양한 행사가격과 만기일에 대한 Centerra Gold의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Centerra Gold에 대한 시장 심리를 평가합니다..

Centerra Gold (NYSE:CGAU) 주식, 옵션 체인

Centerra Gold

Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.

Macro,View,Of,Stacks,Of,Gold,Bars

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AAAU

CGAU

Market Vectors ETF Trust Market Vectors Gold Miners

GLDM

GOLD

PAAS

RGLD

SSRM

TFPM

월요일(21일) 금 가격이 사상 최고치로 급등했다. 금은 월요일 오전 11시 20분(동부표준시 기준) 온스당 2.5% 상승한 3,410달러로 상승했다. 이는 미국 금융자산에 대한 불신과 인플레이션 우려로 인해 2010년대 초 글로벌 부채 위기 이후 볼 수 없었던 안전자산으로의 도피가 이어지는 것을 의미한다.

금 가격 사상 최고치, 2011년 이후 가장 강력한 2개월 랠리···엄청난 금 ETF 매수세도 주목

Gold.goldbar.goldnugget.shutterstock

Equities

News

Analyst Ratings

Trading Ideas

금 가격은 그의 장기 목표가인 온스당 3,000달러를 넘어섰으며, 투자 수요가 10% 증가하면 3,500달러까지 상승할 가능성이 있다고 전망했다.

금 랠리, 중앙은행 매입 및 중국의 배분으로 모멘텀 얻을 수 있어 - BofA

Centerra Gold Inc

Pat Gelsinger, the former CEO of Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), expressed admiration for Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and its superior performance in the artificial intelligence chip market.
What Happened: Gelsinger praised Nvidia&#8217;s ability in an <a href="https://youtu.be/7fmz9gHDgJU?feature=shared">interview</a> with Yahoo Finance to outperform competitors, attributing its success to two main factors: execution and a competitive advantage in AI products.
Gelsinger, who <a href="https://www.benzinga.com/25/03/44506966/former-intel-boss-pat-gelsinger-says-trumps-tariffs-are-helpful-for-us-chip-comeback-but-it-needs-more-than-tsmcs-100-billion-pledge-reveals-the-one-missing-piece">resigned as Intel&#8217;s CEO in December</a>, praised Nvidia Co-Founder and CEO Jensen Huang for his leadership. He stated, &#8220;They are executing well. At the end of the day, Jensen is on it — driving his teams to stay in the front end.&#8221;
He also acknowledged Nvidia&#8217;s ability to &#8220;run hard to stay in the front&#8221; in the silicon AI accelerator market, a sector experiencing significant growth due to increased spending from large companies and the emergence of AI startups.
See Also: <a href="https://www.benzinga.com/tech/25/04/44890247/openais-codex-cli-intels-reshuffle-and-nvidias-500b-commitment-this-week-in-artificial-intelligence">OpenAI&#8217;s Codex CLI, Intel&#8217;s Reshuffle, And Nvidia&#8217;s $500B Commitment: This Week In Artificial Intelligence</a>
Why It Matters: According to Gelsinger, Nvidia&#8217;s second strength lies in building &#8220;meaningful moats,&#8221; or sustainable advantages that shield the company from competition. He cited Nvidia&#8217;s NVLink and CUDA technologies as examples of these competitive moats.
Gelsinger&#8217;s remarks <a href="https://www.benzinga.com/25/03/44506966/former-intel-boss-pat-gelsinger-says-trumps-tariffs-are-helpful-for-us-chip-comeback-but-it-needs-more-than-tsmcs-100-billion-pledge-reveals-the-one-missing-piece">coincide with Intel&#8217;s struggles</a>, which include a 45% decline in the company&#8217;s share price in the previous year. In his first public appearance as CEO, Lip-Bu Tan, Intel&#8217;s new CEO, recently admitted the company&#8217;s flaws.
Intel outperforms rivals Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) on valuation metrics, but Huang-led Nvidia excels in momentum and growth, according to Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Sign up to learn more</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44916245/congress-could-greenlight-trumps-big-beautiful-tax-bill-by-summer-things-are-moving-very-very-quickly-says-hassett">Congress Could Greenlight Trump&#8217;s &#8216;Big Beautiful&#8217; Tax Bill By Summer: &#8216;Things Are Moving Very, Very Quickly,&#8217; Says Hassett</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

INTC

NVDA

Nvidia CEO Jensen Huang Earns Praise From Former Intel CEO Pat Gelsinger: 'Run Hard To Stay In The Front'

HC Wainwright &amp; Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $185 to $168.

Price Target

NBIX

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $168

As <a href="https://www.benzinga.com/25/04/44915268/nasdaq-dips-over-400-points-amid-plunge-in-tesla-nvidia-shares-investor-fear-eases-but-fear-greed-index-remains-i">U.S. stocks continue to slide</a> in spite of robust corporate earnings, CNBC's Jim Cramer says the <a href="https://www.benzinga.com/25/04/44914873/walgreens-to-pay-up-to-350m-for-illegal-opioid-prescriptions-doj-says">downturn</a> does not have much to do with fundamentals, and everything to do with political and economic chaos.
What Happened: Cramer said on Monday that the sell-off harks back to the 2011 Eurozone crisis, calling it "a very manufactured crisis — something man-made that can be un-made with the stroke of a pen." He observed that solid earnings are being overshadowed by outside factors.
See Also: <a href="https://www.benzinga.com/25/04/44915795/tom-lee-urges-bessent-and-lutnick-to-put-points-on-the-board-for-a-positive-policy-shock-to-the-stock-market">Tom Lee Urges Bessent And Lutnick To &#8216;Put Points On The Board&#8217; For A &#8216;Positive Policy Shock&#8217; To The Stock Market</a>
Why It Matters: With widespread anxiety over tariffs, increasing political pressure on the Fed, and impending debt ceiling battles, investors may disregard earnings entirely. "Earnings won't matter in this environment," Cramer said, warning of possible U.S. credit downgrades akin to 2011.
Unless leaders make efforts to stabilize sentiment, Cramer says markets will keep going downhill. "Long story short, we need to get used to a market that's down every morning because the earnings won't matter in this environment," he said. "It will be the tariffs and the talk about firing <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44910907/top-fed-voices-defend-powell-slam-trumps-attack-on-central-bank-independence">Jay Powell</a> that define this period."
As of Monday's close, the Nasdaq 100 had fallen 19.86% from its record high of 22,222.61. The S&amp;P 500 was down 16.09% from its peak of 6,147.43, while the Dow Jones sat 18.09% below its 52-week high of 45,073.63.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/04/44915727/gold-tops-3500-as-investors-flee-to-safety-mohamed-el-erian-warns-of-global-system-shift-amid-trump-powell-tensions">Gold Tops $3,500 As Investors Flee To Safety: Mohamed El-Erian Warns Of Global System Shift Amid Trump-Powell Tensions</a></li>
</ul>
Photo courtesy: katz / Shutterstock.com

Jim Cramer Calls It A 'Manufactured Crisis' As Markets Plunge Despite Strong Earnings

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

Reiteration

INSM

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.26 by 18.25 percent. This is a 81.71 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $9.00 billion which met the analyst consensus estimate. This is a 43.94 percent decrease over sales of $16.05 billion the same period last year.

Earnings

Earnings Beats

GE Aero Q1 2025 Adj EPS $1.49 Beats $1.26 Estimate, Sales $9.00B Inline

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Sernova Biotherapeutics (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SVA#TSX">SVA</a>) with a Buy and maintains C$6 price target.

TSX:SVA

HC Wainwright & Co. Reiterates Buy on Sernova Biotherapeutics, Maintains C$6 Price Target

BNAI

Brand Engagement Network Inc. Announces The Generally Available (GA) Release Of Its iSKYE Platform To Enable Businesses To Quickly Deploy And Scale Customized Ai Solutions With Enterprise Grade Security, Flexibility And Control

General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is facing a lawsuit filed by customers in Georgia for allegedly collecting and selling their driving information without consent.
What Happened: In the filing, plaintiffs said they had a &#8220;reasonable expectation of privacy&#8221; when driving on the road. Plaintiffs also claim GM has violated the Federal Wiretap Act, the Stored Communications Act, and the Computer Fraud and Abuse Act; all of which the company denies.
GM states that ‘driving a vehicle, which necessarily involves conduct that takes place on public roads, cannot form the basis for any privacy-based claims,' <a href="https://www.motor1.com/news/757240/general-motors-sells-data-public-roads/">noted</a> Motor1 on Monday.
‘Driving data includes vehicle location, driving routes, braking events, and speed, all of which occur on "public thoroughfares,"' GM states in their filing to dismiss the case.
Besides GM, the defendants also include data analytics companies NexisLexis and Verisk Analytics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>). Both companies also maintain similar positions to GM in their court filings to dismiss the case.
Why It Matters: GM has had previous run-ins with privacy laws, as the FTC had banned the company and its unit, OnStar, from <a href="https://www.benzinga.com/25/01/43051842/ftc-bans-general-motors-from-sharing-driver-data-following-allegations-that-it-sold-sensitive-consumer-information">disclosing driver information</a> to consumer reporting agencies in January.
"GM monitored and sold people&#8217;s precise geolocation data and driver behavior information, sometimes as often as every three seconds,&#8221; said FTC Chair Lina M Khan at the time of the announcement.
In the midst of this filing in Georgia, GM faces uncertainty as Donald Trump's auto tariffs continue to cast a doubt over the <a href="https://www.benzinga.com/news/25/04/44806252/trump-tariffs-could-put-ford-gm-at-high-risk-of-negative-ratings-report">company's ratings</a>. The tariffs could potentially cost GM and other auto manufacturers <a href="https://www.benzinga.com/25/04/44756759/new-research-shows-donald-trumps-25-tariffs-could-cost-auto-companies-108billion-report">billions of dollars</a>.
Elsewhere, GM had announced it will continue to manufacture EVs at its Ramos Azirpe <a href="https://www.benzinga.com/markets/25/04/44916042/general-motors-has-no-plans-to-move-ev-production-away-from-mexico-despite-tariff-uncertainty">production facility in Mexico</a>, amid uncertainty about auto tariffs.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44777097/gm-halts-electric-van-production-in-ontario-amid-sluggish-sales-1200-employees-affected">GM Halts Electric Van Production In Ontario Amid Sluggish Sales: 1,200 Employees Affected</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

General

VRSK

General Motors Faces Lawsuit For Violation Of Customers' Privacy: Report

CMPS

Compass Pathways Completes Dosing In Part A Of Phase 3 COMP005 Trial Of COMP360 Psilocybin For Treatment-Resistant Depression

HC Wainwright &amp; Co. analyst Andrew Fein maintains Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy and maintains $80 price target.

GPCR

HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Maintains $80 Price Target

DXC Technology Launches Generative AI Offering DXC AI Workbench To Combine Consulting, Engineering, And Secure Enterprise Services

Health Care

REGN

FUJIFILM Diosynth Biotechnologies Ink 10-Year Manufacturing Supply Agreement Worth $3B With Regeneron Pharmaceuticals

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Uranium Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UROY#NASDAQ">UROY</a>) with a Buy and lowers the price target from $7.7 to $4.5.

UROY

HC Wainwright & Co. Maintains Buy on Uranium Royalty, Lowers Price Target to $4.5

&nbsp;Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo.

Biotech

Compass Pathways Announced That All Participants Have Completed Dosing In Part A Of The COMP005 Phase 3 Trial For Treatment-Resistant Depression; The Company Is On Track To Disclose Top-line 6-week Primary Endpoint Results In Late June

Every year, billions of tax-free healthcare dollars go unspent in the U.S., and retailers have set their eyes on them. Flexible Spending Accounts (FSAs) and Health Savings Accounts (HSAs), intended to offset medical costs, are becoming a major sales target for health, wellness, and beauty brands.
What Happened: Retailers like Sephora, Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), and Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) are coming up with tools to assist shoppers in using FSA/HSA funds on eligible items like SPF products, acne treatments, and wellness tech, according to <a href="https://www.retaildive.com/news/fsa-hsa-healthcare-shopper-awareness-beauty-retail-wellness/745339/">a</a> Retail Dive report.
Online resources, shopping guides, and in-store campaigns are leading the charge. "We launched cash register takeovers and out-of-home placements featuring top eligible items," said Lisa Tamburello, VP at Ulta Beauty.
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/44831829/amazons-aggressive-price-cuts-hurt-sephoras-us-sales-says-lvmh-cfo-cecile-cabanis-we-try-to-avoid-this-technique">Amazon&#8217;s Aggressive Price Cuts Hurt Sephora&#8217;s US Sales, Says LVMH CFO Cecile Cabanis: &#8216;We Try To Avoid This Technique</a>
Why It Matters: In Numerator analyst Shawn Paustian's estimation, almost 10%—worth billions—is forfeited each year. Many consumers find it difficult to recognize eligible products. "When presented with a list of eligible items, consumers could only correctly identify less than half," Paustian said.
Retailers identify immense potential in educating account holders, particularly among white-collar professionals who make up most of this market. "FSA/HSA spending in beauty can redefine how consumers think about their routines," said Laura Unger of Sephora.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44850223/march-retail-sales-exceed-forecasts-says-analyst">March Retail Sales Exceed Forecasts, Analyst Notes Best-Performing Sectors</a></li>
</ul>
Photo Courtesy: Steve Heap On Shutterstock.com

Retail Sales

ULTA

Retailers Target Billions In Unused FSA/HSA Funds With Wellness And Beauty Push

<a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">Digital asset investment products</a> recorded modest net inflows of $6 million last week, reflecting an overall mixed investor sentiment, according to the latest CoinShares report.
What Happened: The <a href="https://blog.coinshares.com/volume-230-digital-asset-fund-flows-weekly-report-c905b0aeed15">report</a> highlights regional divergences and asset-specific trends, as investors responded to stronger-than-expected U.S. economic data and shifting macro conditions.
"Sentiment remains highly volatile, with substantial intra-week outflows triggered by unexpectedly strong U.S. retail sales," the CoinShares team noted. 
Specifically, U.S.-based products saw $71 million in outflows, while Europe and Canada showed more positive momentum. Switzerland led with $43.7 million in inflows, followed by Germany with $22.3 million and Canada with $9.4 million.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) remained the focal point for most investors, although sentiment was divided. 
Intra-week movements fluctuated significantly before settling with minor net outflows of $6 million. 
Short Bitcoin products also saw their seventh consecutive week of outflows, dropping by $1.2 million, bringing total seven-week outflows to $36 million, or 40% of all assets under management for those products.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44907123/ripple-coinbase-solana-among-crypto-firms-contributing-over-12m-to-trumps-inauguration-fund">Ripple, Coinbase, Solana Among Crypto Firms Contributing Over $12M To Trump&#8217;s Inauguration Fund</a>
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) continued its persistent streak of underperformance, posting outflows of $26.7 million last week. 
This brings Ethereum's eight-week outflow total to $772 million, underscoring sustained investor caution. 
Despite this, Ethereum still ranks second in year-to-date inflows, with $215 million, suggesting some institutional resilience.
In contrast, XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) defied broader trends with inflows of $37.7 million, making it the third-best performing asset this year in terms of net inflows. 
XRP has now accumulated $214 million in inflows for 2025, reflecting growing confidence from investors amid the asset's regulatory clarity and expanding institutional interest.
What&#8217;s Next: CoinShares' data reflects how digital asset flows remain closely tied to macroeconomic indicators and regional regulatory sentiment.
The report emphasizes that while investor behavior was cautious, especially in the U.S., optimism remains strong in selected European markets and for select altcoins.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44901448/5-catalysts-that-could-drive-bitcoin-higher-bernstein">5 Catalysts That Could Drive Bitcoin Higher: Bernstein</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$XRP

XRP Leads, Ethereum Bleeds As Crypto Investment Products See $6 Million In Inflows

EXAS

Exact Sciences launch of Oncodetect A New Test Designed To Detect Molecular Residual Disease (MRD) Across Multiple Solid Tumors

Guidance

For FY2025, Danaher Initiates Adjusted EPS Guidance Of $7.60 To $7.75 Vs. Consensus Of $7.68, Reaffirms That Non-GAAP Core Revenue Will Grow Approximately 3% Year-Over-Year

Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) with a Buy and raises the price target from $8.5 to $8.75.

SURG

Ascendiant Capital Maintains Buy on Surgepays, Raises Price Target to $8.75

Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) reported quarterly earnings of $0.68 per share which missed the analyst consensus estimate of $0.73 by 6.85 percent. This is a 19.05 percent decrease over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $113.00 million which beat the analyst consensus estimate of $112.71 million by 0.25 percent. This is a 0.10 percent decrease over sales of $113.11 million the same period last year.

Earnings Misses

PEBO

Peoples Bancorp Q1 GAAP EPS $0.68 Misses $0.73 Estimate, Sales $113.00M Beat $112.71M Estimate

Press Releases

Centerra Gold Provides Notice of Fourth Quarter 2024 Results Release and Conference Call

Grid Battery Metals Update - Fall 2024 Drilling Results on Its Clayton Valley Lithium Project

Centerra Gold Reports Fourth Quarter and Full Year 2024 Results and 2025 Outlook; Strong Cash Flow from Operating Activities and $625 Million in Cash and Cash Equivalents

Centerra Gold Announces 2024 Year-End Mineral Reserves and Resources, Including an Initial Resource at Goldfield; Provides Exploration Update

Dividends

Centerra Gold Announces Quarterly Dividend of C$0.07 per Common Share

Management

Centerra Gold Announces Executive Changes

Grid Battery Closes Acquisition of Copper Property with  AC/DC Battery Metals Inc

Centerra Gold Files Annual Report on Form 40-F

Centerra Gold Provides Notice of First Quarter 2025 Results and Conference Call and Details for Annual Meeting of Shareholders

Comments

Centerra Gold

Centerra Gold (CGAU) 옵션

Centerra Gold (NYSE:CGAU) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌